Emodin-Conjugated PEGylation of Fe₃O₄ Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]

This article refers to:

Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer

Ren S, Song L, Tian Y, et al. Int J Nanomedicine. 2021;16:7463–7478.

Page 7466, Cell Viability Assay and Apoptosis Analyses section, 3^rd sentence, the text “Next, different concentrations of Fe₃O₄-PEG and Fe₃O₄-PEG-Cy7-EMO (0, 12.5, 25, 50, 80, 100 μg/mL) were added to the plates and incubated for 24 hours” should read “Next, different concentrations of Fe₃O₄-PEG and Fe₃O₄-PEG-Cy7-EMO (0, 6, 12, 25, 50, 80, 100 μg/mL) were added to the plates and incubated for 48 hours”.

Page 7473, Table 1, the value “62.23%” in the BxPC-3 row for the Fe₃O₄-PEG-Cy7-EMO (80µg/mL) column should read “62.63%”.

Page 7474, Figure 7A, due to an error at the time of figure assembly, the images for spleen and lung in the second and the third rows are identical. The correct Figure 7 is shown below.

Figure 7 (A) The H&E staining of different organs including hearts, livers, spleens, lungs, and kidneys. No obvious pathological changes were observed. (B) Prussian Blue staining analyses of ex vivo.

The authors apologize for these errors and advise they do not affect the results of the paper.